Amrinone in pediatric refractory septic shock: An open-label pharmacodynamic study.

OBJECTIVE: To investigate the short-term hemodynamic effects of amrinone in pediatric patients with refractory septic shock. DESIGN: Open-label, clinical trial. SETTING: Pediatric intensive care unit. PATIENTS: Nine patients admitted with a diagnosis of septic shock receiving stable doses of vasopressors and inotropes. INTERVENTIONS: Pediatric patients with septic shock and a pulmonary artery catheter were treated with amrinone in a stepwise fashion at 5, 10, and 15 &mgr;g/kg/min. MEASUREMENTS AND MAIN RESULTS: Heart rate, blood pressure, cardiac index, rate pressure product, systemic vascular resistance index, pulmonary vascular resistance, oxygen delivery, and oxygen consumption were measured at baseline and 90 mins after each amrinone dose. The addition of amrinone increased cardiac index (p <.05) and oxygen delivery (p <.05) without increasing the rate pressure product. Decreases were observed in systemic vascular resistance index (p <.05) and pulmonary vascular resistance (p <.05). No significant changes were seen in heart rate, blood pressure, or oxygen consumption. CONCLUSIONS: In this short-term, dose-response study in children with refractory septic shock, amrinone improved cardiac index and oxygen delivery in pediatric patients with refractory septic shock without increasing myocardial work.